Patent
Modified T lymphocytes comprising an inducible caspase and methods of apoptosis
Reads0
Chats0
TLDR
In this article, T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., T lymphocytes, were used to treat diseases such as cancer.Abstract:
Provided herein are cells, e.g., T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., cells (e.g., T lymphocytes) expressing the cell death polypeptide, when the cell death polypeptide is multimerized or dimerized. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer.read more
References
More filters
Journal ArticleDOI
Inducible apoptosis as a safety switch for adoptive cell therapy
Antonio Di Stasi,Siok-Keen Tey,Gianpietro Dotti,Yuriko Fujita,Alana A. Kennedy-Nasser,Caridad Martinez,Karin Straathof,Enli Liu,April G. Durett,Bambi Grilley,Hao Liu,Conrad Russell Y. Cruz,Barbara Savoldo,Adrian P. Gee,John Schindler,Robert A. Krance,Helen E. Heslop,David M. Spencer,Cliona M. Rooney,Malcolm K. Brenner +19 more
TL;DR: The inducible T-cell safety switch based on the fusion of human caspase 9 to a modified human FK-binding protein, allowing conditional dimerization may increase the safety of cellular therapies and expand their clinical applications.
Journal ArticleDOI
An inducible caspase 9 safety switch for T-cell therapy
Karin Straathof,Martin Pule,Patricia Yotnda,Gianpietro Dotti,Elio F. Vanin,Malcolm K. Brenner,Helen E. Heslop,David M. Spencer,Cliona M. Rooney +8 more
TL;DR: A "safety switch" that can be stably and efficiently expressed in human T cells without impairing phenotype, function, or antigen specificity is described, based on a modified human caspase 9 fused to a human FK506 binding protein to allow conditional dimerization using a small molecule pharmaceutical.
Patent
Use of chimeric antigen receptor-modified t cells to treat cancer
TL;DR: In this article, the authors present compositions and methods for treating cancer in a human, which includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, costimulatory signaling region, and a CD3 zeta signaling domain.
Patent
Single-chain multivalent binding proteins with effector function
Peter Armstrong Thompson,Jeffrey A. Ledbetter,Martha Hayden-Ledbetter,Laura Sue Grosmaire,Robert Bader,William Brady +5 more
TL;DR: In this article, multivalent binding peptides, including bi-specific binding peptide, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using these peptides to treat or prevent a variety of diseases, disorders or conditions, and to ameliorate at least one symptom associated with such a disease, disorder or condition.
Journal ArticleDOI
A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease
Daniel C. Thomis,Sarah Marktel,Chiara Bonini,Catia Traversari,Michael Z. Gilman,Claudio Bordignon,Tim Clackson +6 more
TL;DR: T cells were eliminated regardless of their proliferation state, suggesting that the AP1903/Fas system, which contains only human components, is a promising alternative to HSV-tk for treating GVHD.